 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CARBAMAZEPINE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CARBAMAZEPINE increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CARBAMAZEPINE increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CARBAMAZEPINE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m            No extracts found! You can try doing a web search with the[0m
[31m            `relevant_search_extracts` or `drug_category_search`[0m
[31m            tools/function-calls.[0m
[31m            [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"CARBAMAZEPINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: CARBAMAZEPINE: warnings: SJS/TEN and HLA-B*[0m[1;31m1502[0m[31m Allele Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of [0m
[31mdeveloping SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*[0m[1;31m1502[0m[31m. The occurrence of higher rates of these reactions in countries with higher [0m
[31mfrequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity. Across Asian populations, notable variation exists in the prevalence of HLA-B*[0m[1;31m1502[0m[31m. [0m
[31mGreater than [0m[1;31m15[0m[31m% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about [0m[1;31m10[0m[31m% in Taiwan and [0m[1;31m4[0m[31m% in North China. South Asians, including [0m
[31mIndians, appear to have intermediate prevalence of HLA-B*[0m[1;31m1502[0m[31m, averaging [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m%, but higher in some groups. CARBAMAZEPINE: warnings: HLA-B*[0m[1;31m1502[0m[31m is present in <[0m[1;31m1[0m[31m% of the population in Japan and Korea.[0m
[31mHLA-B*[0m[1;31m1502[0m[31m is largely absent in individuals not of Asian origin [0m[1;31m([0m[31me.g., Caucasians, African-Americans, Hispanics, and Native Americans[0m[1;31m)[0m[31m. Prior to initiating carbamazepine extended-release capsules [0m
[31mtherapy, testing for HLA-B*[0m[1;31m1502[0m[31m should be performed in patients with ancestry in populations in which HLA-B*[0m[1;31m1502[0m[31m may be present. In deciding which patients to screen, the rates provided above for the [0m
[31mprevalence of HLA-B*[0m[1;31m1502[0m[31m may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic [0m
[31mancestry, and the likelihood of mixed ancestry. Carbamazepine extended-release capsules should not be used in patients positive for HLA-B*[0m[1;31m1502[0m[31m unless the benefits clearly outweigh the risks. [0m
[31mCARBAMAZEPINE: warnings: Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS/Laboratory Tests [0m[1;31m)[0m[31m. Over [0m[1;31m90[0m[31m% of [0m
[31mcarbamazepine treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration in determining the need for [0m
[31mscreening of genetically at-risk patients currently on carbamazepine extended-release capsules. The HLA-B*[0m[1;31m1502[0m[31m allele has not been found to predict risk of less severe adverse cutaneous reactions from[0m
[31mcarbamazepine, such as maculopapular eruption [0m[1;31m[[0m[31mMPE[0m[1;31m][0m[31m or to predict Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m. CARBAMAZEPINE: warnings: Limited evidence suggests that HLA-B*[0m[1;31m1502[0m[31m may [0m
[31mbe a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to [0m
[31mavoiding use of other drugs associated with SJS/TEN in HLA-B*[0m[1;31m1502[0m[31m positive patients, when alternative therapies are otherwise equally acceptable. Patients should be made aware that carbamazepine [0m
[31mextended-release capsules contain carbamazepine and should not be used in combination with any other medications containing carbamazepine. Hypersensitivity Reactions and HLA-A*[0m[1;31m3101[0m[31m Allele [0m
[31mRetrospective case-control studies in patients of European, Korean, and Japanese ancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence [0m
[31mof HLA-A*[0m[1;31m3101[0m[31m, an inherited allelic variant of the HLA-A gene, in patients using carbamazepine. CARBAMAZEPINE: warnings: These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and [0m
[31mDrug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31msee DRESS/Multiorgan hypersensitivity below[0m[1;31m)[0m[31m. HLA-A*[0m[1;31m3101[0m[31m is expected to be carried by more than [0m[1;31m15[0m[31m% of patients of Japanese, Native American, [0m
[31mSouthern Indian [0m[1;31m([0m[31me.g., Tamil Nadu[0m[1;31m)[0m[31m and some Arabic ancestry; up to about [0m[1;31m10[0m[31m% in patients of Han Chinese, Korean, European, Latin American and other Indian ancestry; and up to about [0m[1;31m5[0m[31m% in [0m
[31mAfrican-Americans and patients of Thai, Taiwanese, and Chinese [0m[1;31m([0m[31mHong Kong[0m[1;31m)[0m[31m ancestry. The risks and benefits of carbamazepine therapy should be weighed before considering carbamazepine in patients [0m
[31mknown to be positive for HLA-A*[0m[1;31m3101[0m[31m. General Information on HLA Genotyping and Hypersensitivity Application of HLA genotyping as a screening tool has important limitations and must never substitute [0m
[31mfor appropriate clinical vigilance and patient management. CARBAMAZEPINE: warnings: Many HLA-B*[0m[1;31m1502[0m[31m-positive and HLA-A*[0m[1;31m3101[0m[31m-positive patients treated with carbamazepine will not develop SJS/TEN or [0m
[31mother hypersensitivity reactions, and these reactions can still occur infrequently in HLA-B*[0m[1;31m1502[0m[31m-negative and HLA-A*[0m[1;31m3101[0m[31m-negative patients of any ethnicity. The role of other possible factors in the [0m
[31mdevelopment of, and morbidity from, SJS/TEN and other hypersensitivity reactions, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have [0m
[31mnot been studied. Aplastic Anemia and Agranulocytosis Aplastic anemia and agranulocytosis have been reported in association with the use of carbamazepine. [0m[1;31m([0m[31mSee BOXED WARNING .[0m[1;31m)[0m[31m Patients with a history[0m
[31mof adverse hematologic reaction to any drug may be particularly at risk of bone marrow depression. CARBAMAZEPINE: warnings: Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m/[0m[31mMultiorgan[0m[31m [0m
[31mHypersensitivity Drug Reaction with Eosinophilia and Systemic Symptoms [0m[1;31m([0m[31mDRESS[0m[1;31m)[0m[31m, also known as multiorgan hypersensitivity, have occurred with carbamazepine. Some of these events have been fatal or [0m
[31mlife-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy and/or facial swelling in association with other organ system involvement, such as hepatitis, [0m
[31mnephritis, hematologic abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other [0m
[31morgan systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity [0m[1;31m([0m[31me.g., fever, lymphadenopathy[0m[1;31m)[0m[31m may be present even though rash is not evident. If [0m
[31msuch signs or symptoms are present, the patient should be evaluated immediately. CARBAMAZEPINE: warnings: Carbamazepine should be discontinued if an alternative etiology for the signs or symptoms [0m
[31mcannot be established. Hypersensitivity Hypersensitivity reactions to carbamazepine have been reported in patients who previously experienced this reaction to anticonvulsants including phenytoin, [0m
[31mprimidone, and phenobarbital. A history of hypersensitivity reactions should be obtained for patients and their immediate family members. If such history is present, benefits and risks should be [0m
[31mcarefully considered, and, if carbamazepine is initiated, the signs and symptoms of hypersensitivity should be carefully monitored. In patients who have exhibited hypersensitivity reactions to [0m
[31mcarbamazepine, approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% may experience hypersensitivity reactions with oxcarbazepine [0m[1;31m([0m[31mTrileptal Â® [0m[1;31m)[0m[31m. CARBAMAZEPINE: warnings: Anaphylaxis and Angioedema Rare cases of anaphylaxis and [0m
[31mangioedema involving the larynx, glottis, lips, and eyelids have been reported in patients after taking the first or subsequent doses of carbamazepine. Angioedema associated with laryngeal edema can [0m
[31mbe fatal. If a patient develops any of these reactions after treatment with carbamazepine extended-release capsules, the drug should be discontinued and an alternative treatment started. These [0m
[31mpatients should not be rechallenged with the drug. Withdrawal Precipitated Seizure, Status Epilepticus Antiepileptic drugs should not be abruptly discontinued because of the possibility of increased [0m
[31mseizure frequency, including status epilepticus. When in the judgment of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative anticonvulsant medication arises,[0m
[31mthis should be done gradually. CARBAMAZEPINE: warnings: However, in the event of an allergic or hypersensitivity reaction, more rapid substitution of alternative therapy may be necessary. Suicidal [0m
[31mBehavior and Ideation Antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, including carbamazepine extended-release capsules, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any [0m
[31mindication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or [0m
[31mbehavior. Pooled analyses of [0m[1;31m199[0m[31m placebo-controlled clinical trials [0m[1;31m([0m[31mmono- and adjunctive therapy[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m different AEDs showed that patients randomized to one of the AEDs had approximately twice the [0m
[31mrisk [0m[1;31m([0m[31madjusted Relative Risk [0m[1;31m1.8[0m[31m, [0m[1;31m95[0m[31m% CI:[0m[1;31m1.2[0m[31m, [0m[1;31m2.7[0m[1;31m)[0m[31m of suicidal thinking or behavior compared to patients randomized to placebo. CARBAMAZEPINE: warnings: In these trials, which had a median treatment [0m
[31mduration of [0m[1;31m12[0m[31m weeks, the estimated incidence rate of suicidal behavior or ideation among [0m[1;31m27[0m[31m,[0m[1;31m863[0m[31m AED-treated patients was [0m[1;31m0.43[0m[31m%, compared to [0m[1;31m0.24[0m[31m% among [0m[1;31m16[0m[31m,[0m[1;31m029[0m[31m placebo-treated patients, representing [0m
[31man increase of approximately one case of suicidal thinking or behavior for every [0m[1;31m530[0m[31m patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated [0m
[31mpatients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after [0m
[31mstarting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond [0m[1;31m24[0m[31m weeks, the risk of suicidal thoughts or [0m
[31mbehavior beyond [0m[1;31m24[0m[31m weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: CARBAMAZEPINE: spl_medguide: Medication Guide Carbamazepine Extended-Release Capsules [0m[1;31m([0m[31mkarâ€ ba mazâ€™ e peen[0m[1;31m)[0m[31m Medication Guide available at [0m[4;31mhttps://www.apotex.com/products/us/mg.asp[0m[31m Read this [0m
[31mMedication Guide before you start taking carbamazepine extended-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking to [0m
[31myour healthcare provider about your medical condition or treatment. What is the most important information I should know about carbamazepine extended-release capsules? Do not stop taking carbamazepine[0m
[31mextended-release capsules without first talking to your healthcare provider. Stopping carbamazepine extended-release capsules suddenly can cause serious problems. Carbamazepine extended-release [0m
[31mcapsules can cause serious side effects, including: [0m[1;31m1[0m[31m. Carbamazepine extended-release capsules may cause rare but serious rashes that may lead to death. CARBAMAZEPINE: spl_medguide: These serious skin[0m
[31mreactions are more likely to happen within the first four months of carbamazepine extended-release capsules treatment but may occur at later times. These reactions can happen in anyone, but are more [0m
[31mlikely in people of Asian descent. If you are of Asian descent you may need a genetic blood test before you take carbamazepine extended-release capsules to see if you are at a higher risk for serious [0m
[31mskin reactions with this medicine. Symptoms may include: skin rash hives sores in your mouth blistering or peeling of the skin [0m[1;31m2[0m[31m. Carbamazepine extended-release capsules can also cause other types of [0m
[31mallergic reactions or serious problems that may affect organs and other parts of your body such as your liver or blood cells. You may or may not have a rash when you get these types of reactions. [0m
[31mCARBAMAZEPINE: spl_medguide: Call your healthcare provider right away if you have any of these symptoms: swelling of your face, eyes, lips, or tongue trouble swallowing or breathing frequent fevers or[0m
[31mfevers that do not go away frequent infections or an infection that does not go away unusual bruising or bleeding red or purple spots on your body severe fatigue or weakness unexpected muscle pain [0m
[31mthat does not go away swollen glands that do not go away yellowing of your skin or the whites of your eyes loss of appetite [0m[1;31m([0m[31manorexia[0m[1;31m)[0m[31m that does not go away nausea or vomiting that does not go away [0m
[31mThese symptoms may be the first signs of a serious reaction. A healthcare provider should examine you to decide if you should continue taking carbamazepine extended-release capsules. [0m[1;31m3[0m[31m. Like other [0m
[31mantiepileptic drugs, carbamazepine extended-release capsules may cause suicidal thoughts or actions in a very small number of people, about [0m[1;31m1[0m[31m in [0m[1;31m500[0m[31m. CARBAMAZEPINE: spl_medguide: Call your healthcare [0m
[31mprovider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempt to commit suicide new or worse depression new or worse [0m
[31manxiety feeling agitated or restless panic attacks trouble sleeping [0m[1;31m([0m[31minsomnia[0m[1;31m)[0m[31m new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in [0m
[31mactivity and talking [0m[1;31m([0m[31mmania[0m[1;31m)[0m[31m other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in [0m
[31mmood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried [0m
[31mabout symptoms. Do not stop carbamazepine extended-release capsules without first talking to a healthcare provider. Stopping carbamazepine extended-release capsules suddenly can cause serious [0m
[31mproblems. CARBAMAZEPINE: spl_medguide: Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other[0m
[31mcauses. What is carbamazepine extended-release capsule? Carbamazepine extended-release capsule is a medicine used to treat: certain types of seizures [0m[1;31m([0m[31mpartial, tonic-clonic, mixed[0m[1;31m)[0m[31m certain types of [0m
[31mnerve pain [0m[1;31m([0m[31mtrigeminal and glossopharyngeal neuralgia[0m[1;31m)[0m[31m. Carbamazepine extended-release capsule is not a regular pain medicine and should not be used for aches or pains. Who should not take [0m
[31mcarbamazepine extended-release capsules? Do not take carbamazepine extended-release capsules if you: have a history of bone marrow depression are allergic to carbamazepine or any of the ingredients in[0m
[31mcarbamazepine extended-release capsules. See the end of this Medication Guide for a complete list of ingredients in carbamazepine extended-release capsules.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: LISINOPRIL: warnings: WARNINGS General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of [0m
[31meicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding lisinopril and hydrochlorothiazide tablets[0m[1;31m)[0m[31m may be subject to a variety of adverse [0m
[31mreactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin [0m
[31mconverting enzyme inhibitors, including lisinopril. This may occur at any time during treatment. ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black [0m
[31mpatients. LISINOPRIL: warnings: In such cases lisinopril and hydrochlorothiazide tablets should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and [0m
[31msustained resolution of signs and symptoms has occurred. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation[0m
[31msince treatment with antihistamines and corticosteroids may not be sufficient. Very rarely, fatalities have been reported due to angioedema associated with laryngeal edema or tongue edema. Patients [0m
[31mwith involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or [0m
[31mlarynx, likely to cause airway obstruction, subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0[0m[31m. LISINOPRIL: warnings: [0m[1;31m5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway should be promptly [0m
[31mprovided [0m[1;31m([0m[31mSee ADVERSE REACTIONS . [0m[1;31m)[0m[31m Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [0m[1;31m([0m[31msee also [0m
[31mINDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m [0m
[31mtherapy or a neprilysin inhibitor may be at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with ACE inhibitors. [0m
[31mThese patients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. LISINOPRIL: [0m
[31mwarnings: The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be [0m
[31mincluded in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. Anaphylactoid reactions during desensitization: Two patients undergoing desensitizing treatment [0m
[31mwith hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily [0m
[31mwithheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid reactions during membrane exposure: Sudden and potentially life-threatening anaphylactoid reactions have been reported in some[0m
[31mpatients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for anaphylactoid reactions [0m
[31mmust be initiated. LISINOPRIL: warnings: Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis [0m
[31mmembrane or a different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. [0m
[31mHypotension and Related Effects Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of lisinopril use in salt/volume-depleted persons such as [0m
[31mthose treated vigorously with diuretics or patients on dialysis. [0m[1;31m([0m[31mSee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS .[0m[1;31m)[0m[31m Syncope has been reported in [0m[1;31m0.8[0m[31m percent of patients receiving lisinopril [0m
[31mand hydrochlorothiazide tablets. In patients with hypertension receiving lisinopril alone, the incidence of syncope was [0m[1;31m0.1[0m[31m percent.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: CARBAMAZEPINE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m


[31mCONTENT: LISINOPRIL: drug_interactions: Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline[0m
[31min GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. In general, avoid combined use of RAS [0m
[31minhibitors. Monitor blood pressure, renal function, and electrolytes in patients on lisinopril and hydrochlorothiazide tablets and other agents that affect the RAS. Do not coadminister aliskiren with [0m
[31mlisinopril and hydrochlorothiazide tablets in patients with diabetes. Avoid use of aliskiren with PRINZIDE in patients with renal impairment [0m[1;31m([0m[31mGFR <[0m[1;31m60[0m[31m ml/min[0m[1;31m)[0m[31m. Other Agents: Lisinopril has been used [0m
[31mconcomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. LISINOPRIL: drug_interactions: No meaningful clinically important pharmacokinetic [0m
[31minteractions occurred when lisinopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of lisinopril. [0m
[31mAgents Increasing Serum Potassium: Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Use of lisinopril with potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, eplerenone, [0m
[31mtriamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is [0m
[31mindicated, because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Lithium: Lithium toxicity has been reported in patients receiving [0m
[31mlithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. LISINOPRIL: drug_interactions: Lithium toxicity was usually reversible upon discontinuation of lithium and[0m
[31mthe ACE inhibitor. It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium. Gold: Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial [0m
[31mflushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium aurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including lisinopril and[0m
[31mhydrochlorothiazide tablets. mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m [0m
[31mtherapy may be at increased risk for angioedema. [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. LISINOPRIL: [0m
[31mdrug_interactions: [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m Hydrochlorothiazide When administered concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics - potentiation of [0m
[31morthostatic hypotension may occur. Antidiabetic drugs [0m[1;31m([0m[31moral agents and insulin[0m[1;31m)[0m[31m - dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or [0m
[31mpotentiation. Cholestyramine and colestipol resins - Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol [0m
[31mresins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to [0m[1;31m85[0m[31m% and [0m[1;31m43[0m[31m%, respectively. Corticosteroids, ACTH - intensified electrolyte depletion, [0m
[31mparticularly hypokalemia. Pressor amines [0m[1;31m([0m[31me.g. LISINOPRIL: drug_interactions: norepinephrine[0m[1;31m)[0m[31m - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle [0m
[31mrelaxants, nondepolarizing [0m[1;31m([0m[31me.g., tubocurarine[0m[1;31m)[0m[31m - possible increased responsiveness to the muscle relaxant. Lithium - should not generally be given with diuretics. Diuretic agents reduce the renal [0m
[31mclearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with lisinopril and hydrochlorothiazide tablets. [0m
[31mNon-steroidal Anti-inflammatoryDrugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, [0m
[31mpotassium-sparing and thiazide diuretics.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: ENALAPRIL MALEATE: drug_interactions: Other Cardiovascular Agents Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking [0m
[31magents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates potassium loss caused by thiazide-type[0m
[31mdiuretics. Potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, triamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum [0m
[31mpotassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. [0m
[31mPotassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate. ENALAPRIL MALEATE: drug_interactions: Lithium Lithium toxicity has been reported in [0m
[31mpatients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant [0m
[31menalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly [0m
[31mwith lithium. Gold Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium [0m
[31maurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including enalapril maleate. mTOR [0m[1;31m([0m[31mMammalian Target of Rapamycin[0m[1;31m)[0m[31m Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR [0m
[31minhibitor [0m[1;31m([0m[31me.g. ENALAPRIL MALEATE: drug_interactions: temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: CARBAMAZEPINE: information_for_patients: Information for Patients Patients should be informed of the availability of a Medication Guide and they should be instructed to read the Medication [0m
[31mGuide before taking carbamazepine extended-release capsules. Patients should be made aware of the early toxic signs and symptoms of potential hematologic, dermatologic, hypersensitivity, or hepatic [0m
[31mreactions. These symptoms may include, but are not limited to, fever, sore throat, rash, ulcers in the mouth, easy bruising, lymphadenopathy and petechial or purpuric hemorrhage, and in the case of [0m
[31mliver reactions, anorexia, nausea/vomiting, or jaundice. Patients should be advised that, because these signs and symptoms may signal a serious reaction, they must report any occurrence immediately to[0m
[31mtheir physicians. In addition, the patient should be advised that these signs and symptoms should be reported even if mild or when occurring after extended use. CARBAMAZEPINE: [0m
[31minformation_for_patients: Patients should be advised that serious skin reactions have been reported in association with carbamazepine extended-release capsules. In the event a skin reaction should [0m
[31moccur while taking carbamazepine extended-release capsules, patients should consult with their physician immediately [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Patients should be advised that anaphylactic reactions and [0m
[31mangioedema may occur during treatment with carbamazepine extended-release capsules [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Advise patients to immediately report signs and symptoms suggesting angioedema [0m[1;31m([0m[31mswelling of the [0m
[31mface, eyes, lips, or tongue, or difficulty in swallowing or breathing[0m[1;31m)[0m[31m and to stop taking the drug until they have consulted with their healthcare provider. CARBAMAZEPINE: information_for_patients: [0m
[31mPatients, their caregivers, and families should be counseled that AEDs, including carbamazepine, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert [0m
[31mfor the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern [0m
[31mshould be reported immediately to healthcare providers. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use [0m
[31mof any other prescription or nonprescription medications or herbal products. Caution should be exercised if alcohol is taken in combination with carbamazepine therapy, due to a possible additive [0m
[31msedative effect. Since dizziness and drowsiness may occur, patients should be cautioned about the hazards of operating machinery or automobiles or engaging in other potentially dangerous tasks. [0m
[31mCARBAMAZEPINE: information_for_patients: Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of [0m
[31mantiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m [0m[1;31m([0m[31msee Warnings-Usage in Pregnancy [0m[1;31m)[0m[31m. If necessary, the carbamazepine extended-release capsules can[0m
[31mbe opened and the contents sprinkled over food, such as a teaspoon of applesauce or other similar food products. Carbamazepine extended-release capsules or their contents should not be crushed or [0m
[31mchewed. Carbamazepine extended-release capsules may interact with some drugs. Therefore, patients should be advised to report to their doctors the use of any other prescription or non-prescription [0m
[31mmedication or herbal products. Patients, their caregivers, and families should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior [0m
[31mto taking carbamazepine extended-release capsules. CARBAMAZEPINE: information_for_patients: See FDA approved Medication Guide.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mRBAMAZEPINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: CARBAMAZEPINE has been reported to cause rare cases of anaphylaxis and angioedema, which can involve the larynx, glottis, lips, and eyelids. Angioedema associated with laryngeal edema can be [0m
[32mfatal. If a patient develops any of these reactions after treatment with carbamazepine, the drug should be discontinued and an alternative treatment started. These patients should not be rechallenged [0m
[32mwith the drug.[0m

[32mSOURCE: CARBAMAZEPINE label[0m
[32mEXTRACT_START_END: Anaphylaxis and Angioedema Rare cases [0m[32m...[0m[32m should not be rechallenged with the drug.[0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: CARBAMAZEPINE has been reported to cause rare cases of [0m
[34manaphylaxis and angioedema, which can involve the larynx, glottis, lips, and eyelids. Angioedema associated with laryngeal edema can be fatal. If a patient develops any of these reactions after [0m
[34mtreatment with carbamazepine, the drug should be discontinued and an alternative treatment started. These patients should not be rechallenged with the drug.[0m

[34mSOURCE: CARBAMAZEPINE label[0m
[34mEXTRACT_START_END: Anaphylaxis and Angioedema Rare cases [0m[34m...[0m[34m should not be rechallenged with the drug.[0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CARBAMAZEPINE increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if CARBAMAZEPINE increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that CARBAMAZEPINE has been reported to cause rare cases of anaphylaxis and angioedema, which can be fatal if involving the laryngeal edema. Patients who develop such [0m
[32mreactions should discontinue the drug and not be rechallenged with it."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CARBAMAZEPINE increases the risk of angioedema, although such cases are rare."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CARBAMAZEPINE increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if CARBAMAZEPINE increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that CARBAMAZEPINE has been reported to cause rare cases of anaphylaxis and angioedema, which can be fatal if involving the laryngeal edema. Patients who develop such [0m
[34mreactions should discontinue the drug and not be rechallenged with it."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CARBAMAZEPINE increases the risk of angioedema, although such cases are rare."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CARBAMAZEPINE increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if CARBAMAZEPINE increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that CARBAMAZEPINE has been reported to cause rare cases of anaphylaxis and angioedema, which can be fatal if involving the laryngeal edema. Patients who develop such reactions[0m
[31mshould discontinue the drug and not be rechallenged with it.[0m
[31m        -----[0m
[31m        Final answer: CARBAMAZEPINE increases the risk of angioedema, although such cases are rare.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-CARBAMAZEPINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mCARBAMAZEPINE increases the risk of angioedema, although such cases are rare. This is based on the information provided by FDAHandler, which states that CARBAMAZEPINE has been reported to cause rare [0m
[32mcases of anaphylaxis and angioedema, including potentially fatal laryngeal edema. Patients who develop such reactions should discontinue the drug and not be rechallenged with it.[0m
